Search

Search


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

151. GSK Files Regulatory Submission in US for Once-daily Closed Triple Com

GSK Files Regulatory Submission in US for Once-daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD21/11/2016GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) for patients with chronic obstructive pulmonary disease (COPD). This fo


152. GSK Announces Phase lll Study of Mepolizumab Meets Co-primary Endpoint

GSK Announces Phase lll Study of Mepolizumab Meets Co-primary Endpoints and All Secondary Endpoints in Patients with Eosinophilic Granulomatosis with Polyangiitis23/11/2016GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that both co-primary endpoints and all secondary endpoints were met in a pivotal phase III study investigating the efficacy and safety of mepolizumab, an IL-5 antagonist, in patients with relapsing and refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare di


153. GSK Starts Phase III Programme with Daprodustat for Anaemia Associated

GSK Starts Phase III Programme with Daprodustat for Anaemia Associated with Chronic Kidney Disease24/11/2016GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a phase III development programme investigating daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD).The phase III programme includes two studies evaluating the safety and efficacy of daprodustat compared to recombinant hu


154. Orchard Therapeutics Announces Strategic Alliance with Oxford BioMedic

Orchard Therapeutics Announces Strategic Alliance with Oxford BioMedica29/11/2016Orchard Therapeutics (“Orchard”), a biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with serious and life-threatening orphan diseases announces today that it has entered into a strategic alliance with Oxford BioMedica plc (“Oxford BioMedica”) (LSE: OXB), a world-leading company in gene and cell therapy.Under the terms of the collaboration and lice


155. Charnwood Molecular Appoints New Head of Medicinal Chemistry

Charnwood Molecular Appoints New Head of Medicinal Chemistry14/12/2016Loughborough, UK – CRO, Charnwood Molecular Ltd, appoints Dr James Hitchin as its new Head of Medicinal Chemistry to lead its research services laboratories at BioCity, Nottingham.Dr Hitchin brings extensive experience from across multiple therapeutic areas in drug discovery to the Charnwood team.  James has previously held positions at SAFC Pharma, Pfizer Pharmaceuticals and KemFine Oy.  Most recently he was S



Page 31 of 44 ( 219 results in total )
© Catalyst Innovation Portal 2019